Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Subcutaneous Immunoglobulin Replacement for Treatment of Humoral Immune Dysfunction in Patients With Chronic Lymphocytic Leukemia

In this exploratory proof of concept study, researchers determine the prevalence of humoral immunodeficiency in patients with CLL and serum IgG ≥ 400 mg/dL & evaluate the efficacy of SCIG...

FDA Grants Orphan Drug Designation to LAVA-051 for CLL

LAVA-051, a bispecific antibody that activates the immune system to attack CD1d-expressing cancer cells, was given orphan drug designation from the FDA. 

COVID-19 in Patients With Chronic Lymphocytic Leukemia: Clinical Outcome and B- and T-cell Immunity During 13 months in Consecutive Patients

Scientists studied clinical and immunological outcome of Covid-19 in consecutive CLL patients from a well-defined area during month 1–13 of the pandemic. 


First-Line Acalabrutinib, Venetoclax, and Obinutuzumab for Chronic Lymphocytic Leukemia

Researchers found that first-line triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab produced MRD-negative complete remission...

The ASCO Post
Extrinsic Interactions in the Microenvironment In Vivo Activate an Antiapoptotic Multidrug-Resistant Phenotype in CLL

Scientists demonstrate that antiapoptotic multidrug-resistant CLL cells exist in patients de novo and show that these cells persist during proapoptotic treatment, such as venetoclax.

Blood Advances
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

Scientists have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in a prospectively selected group of patients with CLL...

FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia

This study provided evidence that CXCR4/CD5 intraclonal subpopulations can be used to study the regulation of migration of CLL cells.

Four Year Follow-Up From the Phase III Elevate-TN Trial of CLL Patients

Four-year follow-up of the Phase III Elevate-TN study demonstrated the efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy was maintained among CLL patients...

Oncology Times - Latest Articles
Baseline Geriatric Domains & Survival in Older Adults With CLL

Conducting pretreatment geriatric assessments of functional status, social activity, and nutritional status offers vital prognostic information regarding outcomes among older adults with CLL...

Oncology Times - Latest Articles
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia and Richter’s Transformation

RIC-HSCT yields favorable outcomes for patients with high-risk CLL-RT, especially when performed in early remission.

Blood Advances
Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL

The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with CLL/SLL, based on the primary analysis...

The ASCO Post
Immunomodulatory Effects of Different Intravenous Immunoglobulin Preparations in Chronic Lymphocytic Leukemia

This study aims to evaluate the capacity of Pentaglobin and a standard IVIg preparation to affect leukemic and T cells from CLL patients.

Scientific Reports
Targeted PI3K/AKT-Hyperactivation Induces Cell Death in Chronic Lymphocytic Leukemia

Study investigators test the hypothesis that targeted hyperactivation of the phosphatidylinositol-3-phosphate/AKT-signaling pathway may be leveraged to trigger CLL cell death. 

Nature Communications
Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients

In the current study, investigators observe an increased percentage of Tie2-expressing monocytes in CLL patients.

​First-in-Human Study of Novel BCL-2 Inhibitor in R/R CLL

Lisaftoclax, a novel BCL-2 inhibitor, was well-tolerated with no significant new or unmanageable safety findings among patients with CLL and other hematologic malignancies...

Oncology Times - Latest Articles
Utilizing a Unique Cellular Therapeutic in Chronic Lymphocytic Leukemia​

Researchers show—for the first time—that peripheral blood mononuclear cells from CLL patients can be converted into SUPLEXA cells, according to findings presented at ASCO 2021.

Oncology Times - Latest Articles
Four Year Follow-Up From the Phase III Elevate-TN Trial of CLL Patients

Four-year follow-up of the Phase III Elevate-TN study demonstrates the efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy is maintained among CLL patients...

Oncology Times - Latest Articles
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

Using originally designed BTK PROTAC compounds, study investigators show efficient BTK degradation in chronic lymphocytic leukemia cells.

Frontiers in Oncology
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors

miR-29 down-modulation in an intraclonal CLL subpopulation from immune niches allows for higher TRAF4 and increased CD40 responsiveness.

GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL

Results from the phase 3 GENUINE trial show that ublituximab plus ibrutinib is superior to ibrutinib alone for patients with relapsed or refractory high-risk CLL.

Responses to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia

Mauro et al found that only a small minority of patients with CLL developed an adequate immune response to pneumococcal vaccination, with response being more likely in patients who...

The ASCO Post
Proteomic and Bioinformatic Profiling of Neutrophils in CLL Reveals Functional Defects That Predispose to Bacterial Infections

This study describes a molecular signature of neutrophils through proteomic, bioinformatic, and functional analyses linked to a reduced migratory ability, that could lead to increased...

Blood Advances
Ustekinumab-Induced Chronic Lymphocytic Leukemia in a Patient With Psoriatic Arthritis

This is a case report on the development of chronic lymphocytic leukemia in a patient with PsA treated with ustekinumab.

Tissue Factor Pathway Inhibitor Upregulates CXCR7 Expression and Enhances CXCL12-Mediated Migration in Chronic Lymphocytic Leukemia

This study aims to explore the role of TFPI in CXCL12-mediated migration of CLL cells.

Scientific Reports
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

Long-term follow-up is needed, but zanubrutinib holds promise to be an effective therapy for CLL with a manageable side effect profile and will be an exciting addition to the treatment paradigm.

Drug Design, Development and Therapy
Preclinical Evaluation of the Hsp90 Inhibitor SNX-5422 in Ibrutinib Resistant CLL

This study explores the efficacy of the Hsp90 inhibitor, SNX-5422, in CLL.

Journal of Hematology & Oncology
Non-Coding RNAs: The “Dark Side Matter” of the CLL Universe

This review summarizes the main ncRNAs discovered in CLL and the molecular mechanisms by which they are affected and how they influence the development and the progression of the disease.

The Role of Acalabrutinib in Adults With Chronic Lymphocytic Leukemia

The two major classes of drugs that have contributed to this dramatic evolution include the Bruton tyrosine kinase inhibitors and BCL2 inhibitors.

Therapeutic Advances in Hematology
An Unusual Case of Prolymphocytic Leukemia Transformation in a Patient With Chronic Lymphocytic Leukemia

This case recapitulates the challenges in diagnosing and treating B-PLL. 

Journal of Investigative Medicine High Impact Case Reports
Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia

Treatment of patients with CLL harbouring TP53-deficiency requires drugs that promote cell death independently of TP53. 

Cancer Management and Research
Low Expression of ZHX1 and ZHX2 Impacts on the Prognosis of Chronic Lymphocytic Leukemia

This study determines whether the altered expression of ZHX1 and ZHX2 has clinical implications in patients with CLL.

Assessing Technical and Biological Variation in SWATH-MS-Based Proteomic Analysis of Chronic Lymphocytic Leukaemia Cells

This study provides a valuable resource for researchers working on the proteomics of CLL.

Scientific Reports
Genome-Wide Association Study Identifies Risk Loci for Progressive Chronic Lymphocytic Leukemia

This work identifies rs736456 and rs3778076 as prognostic in CLL, demonstrating that disease progression is determined by constitutional genetic variation as well as known somatic drivers.


source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)